<DOC>
	<DOCNO>NCT01834274</DOCNO>
	<brief_summary>The purpose study evaluate efficacy fasiglifam ( TAK-875 ) plus metformin compare sitagliptin plus metformin glycemic control 24-week Treatment Period .</brief_summary>
	<brief_title>Comparison Fasiglifam ( TAK-875 ) With Sitagliptin When Used Combination With Metformin Patients With Type 2 Diabetes</brief_title>
	<detailed_description>The drug test study call TAK-875 . TAK-875 test treat people type 2 diabetes . This study look glycemic control people take TAK-875 addition metformin . The study enroll approximately 620 patient . Participants randomly assign ( chance , like flip coin ) one two treatment groups—which remain undisclosed patient study doctor study ( unless urgent medical need ) : - TAK-875 50 mg - Sitagliptin 100 mg All participant ask take one tablet time day throughout study . All participant ask self-monitor blood glucose level document increase blood glucose symptom hypoglycemia diary . This multi-center trial conduct United States , Latin America , Europe Asia . The overall time participate study 42 week participant make 15 visit clinic . Due potential concern liver safety , balance , benefit treat patient fasiglifam ( TAK-875 ) outweigh potential risk . For reason , Takeda decide voluntarily terminate development activity fasiglifam .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1 . In opinion investigator , capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . Is male female 18 year age old historical diagnosis type 2 diabetes mellitus ( T2DM ) . 4 . Meets one follow criterion : . 1 . Has HbA1c ≥8 % &lt; 10.5 % , stable daily dose ≥1500 mg ( document maximum tolerate dose ( MTD ) ) metformin least 8 week prior Screening . This participant immediately enter Placebo Runin Period accord Study Schedule A , ; 2 . Has HbA1c ≥8 % &lt; 10.5 % , stable daily dose &lt; 1500 mg metformin without document MTD least 8 week prior Screening . After complete Screening Visit , participant metformin dose immediately increase ≥1500 mg ( MTD ) 8 12week Titration/Stabilization Period accord Study Schedule B . Following stable administration metformin ≥1500 mg ( MTD ) 8 week , participant must qualify entry Placebo Runin Period complete Week 3 procedure HbA1c ≥8 % &lt; 10.5 % . 5 . Has treatment antidiabetic agent metformin within 8 week prior Screening ( Exception : participant receive antidiabetic therapy ≤7 day within 8 week prior Screening ) . 6 . Has body mass index ( BMI ) ≤45 kg/m^2 Screening . 7 . Participants regularly use , nonexcluded medication must stable dose regimen least 4 week prior Screening . However , need use prescription overthecounter medication allow discretion investigator . Note : Participants require initiation chronically administer medication ( ) due disease condition diagnose Screening must rescreened new regimen stabilize . 8 . A female participant childbearing potential sexually active nonsterilized male partner agree routinely use adequate contraception signing inform consent throughout duration study 30 day last dose study drug . 9 . Is able willing monitor glucose sponsorprovided home glucose monitor consistently record blood glucose concentration diary . 1 . Has receive investigational compound within 30 day prior Screening receive investigational antidiabetic drug within 3 month prior Screening . 2 . Has randomize previous TAK875 study . 3 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 4 . Has donate receive blood product within 12 week prior Screening plan donate blood study . 5 . Has hemoglobin ≤12 g/dL ( ≤120 g/L ) males ≤10 g/dL ( ≤100 g/L ) females Screening . 6 . Has systolic blood pressure ≥160 mm Hg diastolic blood pressure ≥95 mm Hg Screening Visit . ( If participant meet exclusion criterion , assessment may repeat least 30 minute initial measurement decision make second measurement . ) 7 . Has history cancer remission &lt; 5 year prior Screening . A history basal cell carcinoma stage I squamous cell carcinoma skin allow . 8 . Has alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) level &gt; 2 x upper limit normal ( ULN ) Screening . 9 . Has total bilirubin level &gt; ULN Screening . Exception : participant document Gilbert 's Syndrome participant allow elevated bilirubin level per investigator 's discretion . 10 . Has serum creatinine ≥1.5mg/dL ( ≥133μmol/L ) male ≥1.4 mg/dL ( ≥124 μmol/L ) female and/or estimate glomerular filtration rate ( eGFR ) &lt; 60 mL/min/1.73 m^2 Screening . 11 . Has uncontrolled thyroid disease determine investigator . 12 . Has history laser treatment proliferative diabetic retinopathy within 6 month prior Screening . 13 . Has history pancreatitis . 14 . Has history gastric band gastric bypass surgery within one year prior Screening . 15 . Has know history infection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) . 16 . Had coronary angioplasty , coronary stent placement , coronary bypass surgery , myocardial infarction ( MI ) , unstable angina pectoris , clinically significant abnormal electrocardiogram ( ECG ) , cerebrovascular accident transient ischemic attack within 3 month prior Screening . 17 . Has history hypersensitivity , allergy , anaphylactic reaction ( ) component TAK875 , metformin , sitagliptin . 18 . Has history drug abuse ( define illicit drug use ) history alcohol abuse within 2 year prior Screening . 19 . Has receive exclude medication prior Screening expect receive exclude medication . 20 . If female , pregnant ( confirmed laboratory testing , ie , serum/urine human chorionic gonadotropin ( hCG ) , females childbearing potential ) lactate intend become pregnant , , within 1 month participate study ; intend donate ova time period . 21 . Is unable understand verbal write English language certify translation approve informed consent available . 22 . Has physical psychiatric disease condition judgment investigator may affect life expectancy may make difficult successfully manage follow participant accord protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>